<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055026</url>
  </required_header>
  <id_info>
    <org_study_id>FADOI.01.2016</org_study_id>
    <nct_id>NCT03055026</nct_id>
  </id_info>
  <brief_title>Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.</brief_title>
  <acronym>PRO-LAPSII</acronym>
  <official_title>Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer: a Randomized, Double Blind, Placebo-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fadoi Foundation, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fadoi Foundation, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for
      colorectal cancer: a randomized, double blind, placebo-controlled study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Venous thromboembolism</measure>
    <time_frame>28±2 days from planned laparoscopic surgery for colorectal cancer in patients randomized to rivaroxaban or placebo.</time_frame>
    <description>The primary study outcome is a composite of symptomatic objectively confirmed VTE, asymptomatic ultrasonography-confirmed DVT or VTE-related death.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">646</enrollment>
  <condition>Prevention of Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally administered, at the dose of 10 mg OD for 3 weeks (extended prophylaxis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Orally administered, OD for 3 weeks (extended prophylaxis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Objective diagnosis of colorectal cancer;

          -  Elective laparoscopic surgery for colorectal cancer

          -  Whatever the stage of cancer

          -  Antithrombotic prophylaxis with LMWH administered for 7±2 days after surgery

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Surgery for non-cancer disease

          -  Duration of surgery &lt; 45 min

          -  Conversion to open surgery

          -  Other indication for anticoagulant therapy

          -  Known cerebral metastases

          -  Kidney or liver failure

          -  Known hemorrhagic diathesis or high risk for bleeding

          -  History of intracerebral bleeding or neurosurgery within 6 months

          -  History of heparin induced thrombocytopenia

          -  Pregnancy or lactation

          -  Refusal of informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauro Campanini</last_name>
    <role>Study Director</role>
    <affiliation>FADOI Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cecilia Becattini</last_name>
    <phone>+390755782311</phone>
    <email>cecilia.becattini@unipg.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giancarlo Agnelli</last_name>
    <phone>+390755786424</phone>
    <email>giancarlo.agnelli@unipg.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nuovo Ospedale &quot;San Giovanni Battista&quot;</name>
      <address>
        <city>Foligno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Rondelli</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

